TIAA CREF Investment Management LLC raised its holdings in Coherus BioSciences, Inc. (NASDAQ:CHRS) by 70.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,001,104 shares of the biotechnology company’s stock after buying an additional 414,229 shares during the quarter. TIAA CREF Investment Management LLC owned 1.95% of Coherus BioSciences worth $14,366,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CHRS. Jennison Associates LLC grew its holdings in shares of Coherus BioSciences by 0.4% during the 2nd quarter. Jennison Associates LLC now owns 18,200 shares of the biotechnology company’s stock worth $261,000 after purchasing an additional 69 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Coherus BioSciences by 0.9% during the 2nd quarter. Wells Fargo & Company MN now owns 29,116 shares of the biotechnology company’s stock worth $418,000 after purchasing an additional 253 shares in the last quarter. Nationwide Fund Advisors grew its holdings in shares of Coherus BioSciences by 1.3% during the 1st quarter. Nationwide Fund Advisors now owns 33,982 shares of the biotechnology company’s stock worth $719,000 after purchasing an additional 421 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Coherus BioSciences by 12.6% during the 2nd quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 1,046 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Coherus BioSciences by 32.7% during the 2nd quarter. SG Americas Securities LLC now owns 7,244 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,785 shares in the last quarter. 78.19% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Coherus BioSciences, Inc. (CHRS) Shares Bought by TIAA CREF Investment Management LLC” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/01/coherus-biosciences-inc-chrs-shares-bought-by-tiaa-cref-investment-management-llc.html.

CHRS has been the topic of several recent research reports. Maxim Group decreased their price objective on Coherus BioSciences from $44.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, June 12th. Zacks Investment Research raised Coherus BioSciences from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Tuesday, August 15th. BidaskClub lowered Coherus BioSciences from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Cowen and Company reissued an “outperform” rating and set a $45.00 price objective on shares of Coherus BioSciences in a report on Friday, September 8th. Finally, Credit Suisse Group set a $38.00 price objective on Coherus BioSciences and gave the stock a “buy” rating in a report on Monday, June 12th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $32.00.

In related news, insider Alan C. Herman sold 17,535 shares of the stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $15.02, for a total transaction of $263,375.70. Following the sale, the insider now owns 49,651 shares of the company’s stock, valued at $745,758.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 26.28% of the company’s stock.

Coherus BioSciences, Inc. (CHRS) opened at 13.35 on Friday. The company’s market cap is $685.47 million. The company’s 50 day moving average price is $13.00 and its 200 day moving average price is $17.33. Coherus BioSciences, Inc. has a 52-week low of $10.80 and a 52-week high of $31.48.

Coherus BioSciences (NASDAQ:CHRS) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.29) by $0.21. The business had revenue of $1.40 million for the quarter. Coherus BioSciences had a negative return on equity of 307.41% and a negative net margin of 73.89%. Equities research analysts anticipate that Coherus BioSciences, Inc. will post ($5.13) EPS for the current fiscal year.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Want to see what other hedge funds are holding CHRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Coherus BioSciences, Inc. (NASDAQ:CHRS).

Institutional Ownership by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Stock Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related stocks with our FREE daily email newsletter.